Cg Oncology Is A Late Stage Clinical Biopharmaceutical Company Based In Irvinecathe Company Focuses On Developing And Commercializing Bladder Sparing Therapeutics For Patients With Bladder Canceraiming To Enhance The Quality Of Life For Those Affected By Urologic Cancers Through Innovative Immunotherapies The Main Product Candidate From Cg Oncology Is Cretostimogene Grenadenorepvecan Investigational Engineered Oncolytic Immunotherapythis Therapy Has Demonstrated Clinical Benefits For Treating Bcg Unresponsive Non Muscle Invasive Bladder Cancernmibcand Is Well Tolerated As Both A Standalone Treatment And In Combination With Other Therapiesled By Chairman And Ceo Arthur Kuanalong With President And Coo Ambawcg Oncology Is Committed To Building A Talented Team That Shares Its Visionthe Company Has Successfully Completed An Initial Public Offering To Support Its Development And Commercialization Efforts
